Journal Mobile Options
Table of Contents
Vol. 83, No. 1, 2003
Issue release date: January 2003
Biol Neonate 2003;83:1–5

Can the Administration of Antithrombin III Decrease the Risk of Cerebral Hemorrhagein Premature Infants?

Fulia F. · Cordaro S. · Meo P. · Gitto P. · Gitto E. · Trimarchi G. · Adelardi S. · Barberi I.
aNeonatal Intensive Care Unit, Department of Pediatrics, and bInstitute of Statistics, University of Messina, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants. In a randomized study, 60 infants born before 30 weeks of gestation were assigned to receive a loading dose of antithrombin III or placebo. There was no significant difference in the incidence of intraventricular hemorrhage between the antithrombin III and the placebo group (27.5 vs. 32%). Partial thromboplastin time, Quick’s prothrombin time and platelet count were also not significantly different between the 2 groups. We conclude that the administration of antithrombin III during the first 2 days of life does not decrease incidence of intraventricular hemorrhage. Antithrombin III is a very expensive therapy and its benefits should be carefully investigated before being recommended as valuable therapy.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. McDonald MM, Johnson ML, Rumack CM, Koops BL, Guggenheim MA, Bobb C, Hathaway WE: Role of coagulopathy in newborn intracranial hemorrhage. Pediatrics 1984;74:26–31.
  2. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P: Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651–1657.
  3. Andrew M, Paes B, Johnston M: Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95–104.
  4. Junker R, Koch HG, Auberger K, Munchow N, Ehrenforth S, Nowak-Gottl U: Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999;19:2568–2572.
  5. Petaja J, Hiltunen L, Fellman V: Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 2001;49:643–646.
  6. Manco-Johnson MJ: Disorders of hemostasis in childhood: Risk factors for venous thromboembolism. Thromb Haemost 1997;78:710–714.
  7. Schmidt B, Vegh P, Weitz J, Johnston M, Caco C, Roberts R: Thrombin/antithrombin III complex formation in the neonatal respiratory distress syndrome. Am Rev Respir Dis 1992;145:767–770.
  8. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, Rossi R, D’Angelo A, Crippa L, Giudici D, Gallioli G, Wolfler A, Calori G: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336–342.
  9. Zoller B, Garcia de Frutos P, Hillarp A, Dahlback B: Thrombophilia as a multigenic disease. Haematologica 1999;84:59–70.
  10. Chen JP, Lorch V: Intraventricular haemorrhage in preterm infants: Evidence of suppressed fibrinolysis. Blood Coagul Fibrinolysis 1996;7:289–294.
  11. Fujii Y, Takeuchi S, Harada A, Abe H, Sasaki O, Tanaka R: Hemostatic activation in spontaneous intracerebral hemorrhage. Stroke 2001;32:883–890.

    External Resources

  12. Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evaluation of subependymal ord intraventricular hemorrhage. A study of infants with birth weight less than 1,500 grams. J Pediatr 1978;92:529–534.
  13. Chang GY, Lueder FL, DiMichele DM, Radkowski MA, McWilliams LJ, Jansen RD: Heparin and the risk of intraventricular hemorrhage in premature infants. J Pediatr 1997;131:362–366.
  14. Antoniuk S, da Silva RV: Periventricular and intraventricular hemorrhage in the premature infants. Rev Neurol 2000;31:238–243.
  15. Dehara M, Morimoto K, Takemoto O, Hirano S, Yoshimine T: Germinal matrix hemorrhage and hydrocephalus in premature infants. No To Shinkei 1999;51:627–631.
  16. Paneth N, Pinto-Martin J, Gardiner J, Wallenstein S, Katsikiotis V, Hegyi T, Hiatt IM, Susser M: Incidence and timing of germinal matrix/intraventricular hemorrhage in low birthweight infants. Am J Epidemiol 1993;137:1167–1176.
  17. Smith LM, Qureshi N, Chao CR: Effects of single and multiple courses of antenatal glucocorticoids in pretermnewborns less than 30 weeks’ gestation. J Matern Fetal Med 2000;9:131–135.
  18. Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW: Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. Am J Obstet Gynecol 1995;172:795–800.
  19. Philip AG, Allan WC: Does cesarean section protect against intraventricular hemorrhage in preterm infants? J Perinatol 1991;11:3–9.
  20. Lou HC, Skov H, Pedersen H: Low cerebral blood flow: a risk factor in the neonate. J Pediatr 1979;95:606–609.
  21. Jorch G, Jorch N: Failure of autoregulation of cerebral blood flow in neonates studied by pulsed Doppler ultrasound of the internal carotid artery. Eur J Pediatr 1987;146:468–472.
  22. Chen JP, Lorch V: Intraventricular haemorrhage in preterm infants: Evidence of suppressed fibrinolysis. Blood Coagul Fibrinolysis 1996;7:289–294.
  23. Beverley DW, Chance GW, Inwood MJ, Schaus M, O’Keefe B: Intraventricular haemorrhage and haemostasis defects. Arch Dis Child 1984;59:444–448.

    External Resources

  24. Mercuri E, Cowan F, Gupte G, Manning R, Laffan M, Rutherford M, Edwards AD, Dubowitz L, Roberts I: Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001;107:1400–1404.

    External Resources

  25. Klinger G, Koren G: Antenatal phenobarbital for prevention of intraventricular hemorrhage in preterm infants. Can Fam Physician 2000;46:1285–1287.
  26. Whitelaw A: Postnatal phenobarbitone for the prevention of intraventricular hemorrhage in preterm infants. Cochrane Database Syst Rev 2000;2:CD001691.
  27. Rubino CM, Shaffer CL, Gal P, Ransom JL, Kissling GE: Postnatal pharmacologic prevention of intraventricular hemorrhage: Meta-analysis of phenobarbital and indomethacin. Pediatr Nurs 1997;23:196–204.
  28. De Lia JE, Billman D: Antepartum vitamin K and phenobarbital for preventing intraventricular hemorrhage in the premature newborn: A randomized, double-blind, placebo-controlled trial. Obstet Gynecol 1994;83:1067–1069.
  29. Chen JY: Ethamsylate in the prevention of periventricular-intraventricular hemorrhage in premature infants. J Formos Med Assoc 1993;92:889–893.
  30. Chiswick M, Gladman G, Sinha S, Toner N, Davies J: Vitamin E supplementation and periventricular hemorrhage in the newborn. Am J Clin Nutr 1991;53:370–372.
  31. Sinha S, Davies J, Toner N, Bogle S, Chiswick M: Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies. Lancet 1987;1:466–471.
  32. Kurachi K, Fujikawa K, Schmer G, Davie EW: Inhibition of bovine factors IXa and Xa by antithrombin III. Biochemistry 1976;15:373–377.
  33. Peters M, Ten Cate JW, Jansen E, Bruderveld C: Coagulation and fibrinolytic factors in the first week of live in healthy infants. J Pediatr 1985;106:292–295.
  34. Okajima K, Uchiba M: The anti-inflammatory properties of antithrombin III: New therapeutic implications. Semin Thromb Hemost 1998;24:27–32.
  35. Baudo F, de Cataldo F: Antithrombin III concentrates in the treatment of sepsis and septic shock: Indications, limits and future prospects (in Italian). Minerva Anestesiol 2000;66:3–23.
  36. Brangenberg R, Bodensohn M, Bürger U: Antithrombin-III substitution in preterm infants: Effect on intracranial hemorrhage and coagulation parameters. Biol Neonate 1997;72:76–83.
  37. Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R: A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998;158:470–476.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50